The company's SaaS solutions are tailored to enhance accessibility, efficiency, and patient-centricity in healthcare operations
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
The company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies
The CDCCs are strategically positioned in regions identified as high-impact areas
iSolveSM information on demand is the result of our focus on customer relationship
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion diagnostics business.
The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
These re-agent and diagnostic test kits come with 99.7% accuracy
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
Subscribe To Our Newsletter & Stay Updated
